Details for Patent: 8,969,336
✉ Email this page to a colleague
Which drugs does patent 8,969,336 protect, and when does it expire?
Patent 8,969,336 protects XOSPATA and is included in one NDA.
This patent has forty-eight patent family members in twenty-nine countries.
Summary for Patent: 8,969,336
| Title: | Diamino heterocyclic carboxamide compound |
| Abstract: | Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer. |
| Inventor(s): | Shimada; Itsuro (Tokyo, JP), Kurosawa; Kazuo (Tokyo, JP), Matsuya; Takahiro (Tokyo, JP), Iikubo; Kazuhiko (Tokyo, JP), Kondoh; Yutaka (Tokyo, JP), Kamikawa; Akio (Tokyo, JP), Tomiyama; Hiroshi (Nagano, JP), Iwai; Yoshinori (Nagano, JP) |
| Assignee: | Astellas Pharma Inc. (Tokyo, JP) Kotobuki Pharmaceutical Co., Ltd. (Hanishina-gun, JP) |
| Application Number: | 13/266,164 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,969,336
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | XOSPATA | gilteritinib fumarate | TABLET;ORAL | 211349-001 | Nov 28, 2018 | RX | Yes | Yes | 8,969,336 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,969,336
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2009-113936 | May 8, 2009 |
| PCT Information | |||
| PCT Filed | May 06, 2010 | PCT Application Number: | PCT/JP2010/057751 |
| PCT Publication Date: | November 11, 2010 | PCT Publication Number: | WO2010/128659 |
International Family Members for US Patent 8,969,336
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2428508 | ⤷ Subscribe | 301028 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2428508 | ⤷ Subscribe | 122020000004 | Germany | ⤷ Subscribe |
| European Patent Office | 2428508 | ⤷ Subscribe | PA2020002 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2428508 | ⤷ Subscribe | CA 2020 00006 | Denmark | ⤷ Subscribe |
| European Patent Office | 2428508 | ⤷ Subscribe | LUC00147 | Luxembourg | ⤷ Subscribe |
| European Patent Office | 2428508 | ⤷ Subscribe | 2020C/502 | Belgium | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
